Clinical Trial Update: A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Osimertinib in patients with EGFR-mutated non-small cell lung cancer who progressed after adjuvant targeted therapy following radical s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Jin Ying | Conditions: Lung Neoplasms, Lung Cancer, Nonsmall Cell | Phase 2 | Status: NOT_YET_RECRUITING